HLA-B*58:01 is a risk factor for allopurinol-induced DRESS and Stevens-Johnson syndrome/toxic epidermal necrolysis in a Portuguese population

British Journal of Dermatology

Volumn 169, Issue 3, 2013, Pages 660-665

  Goncalo M ^a   Coutinho, I ^a   Teixeira, V ^a   Gameiro, A R ^a   Brites, M M ^a,b   Nunes, R ^c   Martinho, A ^c  

^a CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

^b UNIVERSITY OF COIMBRA   (Portugal)

^c Centro de Histocompatibilidade do Centro Coimbra   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; HLA ANTIGEN CLASS 1; HLA B58 ANTIGEN; OLIGONUCLEOTIDE; UNCLASSIFIED DRUG; ANTIGOUT AGENT; HLA B ANTIGEN; HLA-B58 ANTIGEN;

ADULT; AGED; ALLELE; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRESS SYNDROME; FEMALE; GENOTYPE; GOUT; HAPLOTYPE; HLA SYSTEM; HUMAN; HYPERURICEMIA; KIDNEY DISEASE; MALE; POLYMERASE CHAIN REACTION; POPULATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; RISK FACTOR; SEX DIFFERENCE; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS; ETHNOLOGY; GENETICS; HOMOZYGOTE; METABOLISM; MIDDLE AGED; PORTUGAL; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ALLOPURINOL; FEMALE; GENOTYPE; GOUT SUPPRESSANTS; HLA-B ANTIGENS; HOMOZYGOTE; HUMANS; MALE; MIDDLE AGED; PORTUGAL; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; RISK FACTORS; STEVENS-JOHNSON SYNDROME; YOUNG ADULT;

EID: 84883343259     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.12389     Document Type: Article

References (50)

1. Hershfield M, Callaghan J, Tassaneeyakul W, et al,. Clinical pharmacogenetics implementation consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing. Clin Pharmacol Ther 2013; 93: 153-8.
2. Kim S, Newcomb C, Margolis D, et al,. Severe cutaneous reactions requiring hospitalization in allopurinol initiators: a population based cohort study. Arthritis Care Res (Hoboken) 2013; 65: 578-84.
3. Halevy S, Ghislain P, Mockenhaupt M, et al,. Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. J Am Acad Dermatol 2008; 58: 25-32.
4. Mockenhaupt M,. Epidemiology of cutaneous adverse drug reactions. Chem Immunol Allergy 2012; 97: 1-17.
5. Huang H, Luo X, Chan L, et al,. Cutaneous adverse drug reactions in a hospital-based Chinese population. Clin Exp Dermatol 2011; 36: 135-41.
6. Lee M, Stocker S, Anderson J, et al,. Initiating allopurinol therapy: do we need to know the patient's human leucocyte antigen status? Intern Med J 2012; 42: 411-16.
7. Atzori L, Pinna A, Mantovani L, et al,. Cutaneous adverse drug reactions to allopurinol: 10 year observational survey of the dermatology department-Cagliari University (Italy). J Eur Acad Dermatol Venereol 2012; 26: 1424-30.
8. Brinca A, Andrade P, Xavier M, et al,. Síndrome de Stevens-Johnson e necrõlise epidérmica tõxica-casuística de 10 anos. Rev Soc Port Dermatol Venereol 2011; 69: 403-11.
9. Kim M, Shim E, Jung J, et al,. A case of allopurinol-induced fixed drug eruption confirmed with a lymphocyte transformation test. Allergy Asthma Immunol Res 2012; 4: 309-10.
10. Teo W, Pang S, Koh H,. Allopurinol hypersensitivity syndrome with acute generalized exanthematous pustulosis manifestations. Cutan Ocul Toxicol 2011; 30: 243-4.
11. Gonçalo M, Bruynzeel D,. Mechanisms in cutaneous drug hypersensitivity reactions. In: Dermatotoxicology (, Wilhem K, Khai H, Maibach H, eds), 8th edn. Boca Raton, FL: CRC Press, 2012; 78-92.
12. Chung W-H, Hung S, Yang J-Y, et al,. Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis. Nat Med 2008; 14: 1343-50.
13. Schlapbach C, Zadowdniak A, Adam A, et al,. NKp46+ cells express granulysin in multiple cutaneous adverse drug eruptions. Allergy 2011; 66: 1469-76.
14. Saito N, Abe R, Yoshioka N, et al,. Prolonged elevation of serum granulysin in drug-induced hypersensitivity syndrome. Br J Dermatol 2012; 147: 452-3.
15. Phillips E, Wong G, Kaul R, et al,. Clinical and immunogenetic correlates of abacavir hypersensitivity. AIDS 2005; 19: 979-87.
16. Phillips E, Mallal S,. Successful translation of pharmacogenetics into the clinic: the abacavir example. Mol Diagn Ther 2009; 13: 1-9.
17. Yang C, Hung S, Juo C, et al,. HLA-B*1502-bound peptides: implications for the pathogenesis of carbamazepine-induced Stevens-Johnson syndrome. J Allergy Clin Immunol 2007; 120: 870-7.
18. Chen P, Lin J, Lu C, et al,. Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan. N Engl J Med 2011; 364: 1126-33.
19. Wei C, Chung W, Huang H, et al,. Direct interaction between HLA-B and carbamazepine activates T cells in patients with Stevens-Johnson syndrome. J Allergy Clin Immunol 2012; 129: 1562-9.
20. McCormack M, Alfirevic A, Bourgeois S, et al,. HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N Engl J Med 2011; 364: 1134-43.
21. Somkrua R, Eickman E, Saokaew S, et al,. Association of HLA-B*5801 allele and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis. BMC Med Genet 2011; 12: 118.
22. Jung J, Song W, Kim Y, et al,. HLA-B58 can help the clinical decision on starting allopurinol in patients with chronic renal insufficiency. Nephrol Dial Transplant 2011; 26: 3567-72.
23. Cao Z, Wei Z, Zhu Q, et al,. HLA-B*58:01 allele is associated with augmented risk for both mild and severe cutaneous adverse reactions induced by allopurinol in Han Chinese. Pharmacogenomics 2012; 13: 1193-201.
24. Chiu M, Hu M, Ng M, et al,. Association between HLA-B*58:01 allele and severe cutaneous adverse reactions with allopurinol in Han Chinese in Hong Kong. Br J Dermatol 2012; 167: 44-9.
25. Kaniwa N, Saito Y, Aihara M, et al,. HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis. Pharmacogenomics 2008; 9: 1617-22.
26. Lonjou C, Borot N, Sekula P, et al,. A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet Genomics 2008; 18: 99-107.
27. Bégaud B, Evreux J, Jouglard J, Lagier G,. [ Imputation of the unexpected or toxic effects of drugs. Actualization of the method used in France. ] Thérapie 1985; 40: 111-18 (in French).
28. Kardaun S, Sidoroff A, Valleyrie-Allanore L, et al,. Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist? Br J Dermatol 2007; 156: 609-12.
29. Roujeau J,. Clinical heterogeneity of drug hypersensitivity. Toxicology 2005; 209: 123-9.
30. Barbaud A, Gonçalo M, Bircher A, Bruynzeel D,. Guidelines for performing skin tests with drugs in the investigation of cutaneous adverse drug reactions. Contact Dermatitis 2001; 45: 321-8.
31. Santiago F, Gonçalo M, Vieira R, et al,. Epicutaneous patch testing in drug hypersensitivity syndrome (DRESS). Contact Dermatitis 2010; 62: 47-53.
32. Pirmohamed M, Friedmann P, Molokhia M, et al,. Phenotype standardization for immune-mediated drug-induced skin injury. Clin Pharmacol Ther 2011; 89: 896-901.
33. Santiago F, Brites M, Cravo M, et al,. Síndrome de hipersensibilidade a fármacos/DRESS: 5 anos de experiência num Serviço de Dermatologia. Trab Soc Port Dermatol Venereol 2008; 66: 541-55.
34. Zineh I, Mummaneni P, Lyndly J, et al,. Allopurinol pharmacogenetics: assessment of potential clinical usefulness. Pharmacogenomics 2011; 12: 1741-9.
35. Hung S, Chung W, Liou L, et al,. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci USA 2005; 102: 4134-9.
36. Tassaneeyakul W, Jantararoungtong T, Chen P, et al,. Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population. Pharmacogenet Genomics 2009; 19: 704-9.
37. Kang H, Jee Y, Kim Y, et al,. Positive and negative associations of HLA class I alleles with allopurinol-induced SCARs in Koreans. Pharmacogenet Genomics 2011; 21: 303-7.
38. Bharadwaj M, Illing P, Theodossis A, et al,. Drug hypersensitivity and human leukocyte antigens of the major histocompatibility complex. Annu Rev Pharmacol Toxicol 2012; 52: 401-31.
39. Yun J, Adam J, Yerly D, Pichler W,. Human leukocyte antigens (HLA) associated drug hypersensitivity: consequences of drug binding to HLA. Allergy 2012; 67: 1338-46.
40. Chessman D, Kostenko L, Lethborg T, et al,. Human leukocyte antigen class-I restricted activation of CD8+ T cells provides the immunogenetic basis of a systemic drug hypersensitivity. Immunity 2008; 28: 822-32.
41. Yun J, Yerly D, Fontana S, Pichler W,. Generation of allopurinol/ oxypurinol specific T cells in vitro. Presented at: Drug Hypersensitivity Meeting-DHM5, Munich, 2012, Programme and Abstract Book, 2012; 126-7.
42. Lin C, Chen Y, Hung S,. The pathogenic role of HLA-B*5801 in allopurinol-induced severe cutaneous adverse reactions. Presented at: Drug Hypersensitivity Meeting-DHM5, Munich, 2012, Programme and Abstract Book, 2012; 125.
43. Hamanaka H, Mizutani H, Nouchi N, et al,. Allopurinol hypersensitivity syndrome: hypersensitivity to oxypurinol but not allopurinol. Clin Exp Dermatol 1998; 23: 32-4.
44. Ko T, Chen YT,. T-cell receptor and carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: understanding a hypersensitivity reaction. Expert Rev Clin Immunol 2012; 8: 467-77.
45. Wei C, Ko T, Shen C, Chen Y,. A recent update of pharmacogenomics in drug-induced severe skin reactions. Drug Metab Pharmacokinet 2012; 27: 132-41.
46. Kostenko L, Kjer-Nielsen L, Nicholson I, et al,. Rapid screening for the detection of HLA-B57 and HLA-B58 in prevention of drug hypersensitivity. Tissue Antigens 2011; 78: 11-20.
47. Kwok J, Kwong K,. Detection of HLA-B*58:01, the susceptible allele for allopurinol induced hypersensitivity, by loop-mediated isothermal amplification. Br J Dermatol 2013; 168: 526-32.
48. Garcia-Valladares I, Khan T, Espinoza L,. Efficacy and safety of febuxostat in patients with hyperuricemia and gout. Ther Adv Musculoskelet Dis 2011; 3: 245-53.
49. Richette P,. [ Gout: an overview of available urate lowering therapies ]. Ann Pharm Fr 2012; 70: 133-8 (in French).
50. Lee M, Stocker S, Williams K, Day R,. HLA-B*5801 should be used to screen for risk of Stevens-Johnson syndrome in family members of Han Chinese patients commencing allopurinol therapy. J Rheumatol 2013; 40: 96-7.